Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talactoferrin + Chemo in First-Line Advanced NSCLC
NCT00706862Phase 3Unknown
- Sponsor
- Agennix AG
- Start
- Feb 2009
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Talactoferrin Arm with Placebo Arm (2 arms). Primary endpoints: Overall Survival and Progression Free Survival. Status: unknown.
02
Drugs
lactoferrin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00706862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706862.